Menu
Dividend AristocratsDividend KingsHigh YieldMonthly DividendDividend CalendarScreener

Lemaitre Vascular Inc. Stock Price History

Lemaitre Vascular Inc. EPS

EPSDividend / share
0.00.71.42.02.7200920112013201520172019202120232025

Lemaitre Vascular Inc. Dividend per Share

Forward Yield
1.08%
Annual Dividend
1.00 USD
Payout
31.25%
Frequency
Quarterly
Yrs of growth
12+
CAGR 5Y
16.05%
Status
Dividend Grower
0.00.20.40.60.92013201520172019202120232025

Lemaitre Vascular Inc. Dividend Yield

Lemaitre Vascular Inc. Payout Ratio

0%16%33%49%66%2013201520172019202120232025

Lemaitre Vascular Inc. Dividend Growth

1Y CAGR
3Y CAGR
5Y CAGR
10Y CAGR
20Y CAGR
25.00%
16.96%
16.05%
17.46%
Compound annual growth rate of dividend per share
Yield vs sector
1.08%
avg Healthcare: 2.97%
Next ex-dividend (est.)
2026-08-20
last: 2026-05-21
Ex-DateAmount
2026-05-210.25 USD
2026-03-120.25 USD
2025-11-200.20 USD
2025-08-210.20 USD
2025-05-150.20 USD
2025-03-130.20 USD
2024-11-210.16 USD
2024-08-150.16 USD

LeMaitre Vascular Inc. develops, manufactures, and markets specialized medical devices and implants designed for vascular surgery and the treatment of peripheral vascular disease. The company offers a comprehensive portfolio of products across six key categories: aortic, arteriovenous access, cardiac, carotid, lower extremity, and neuro applications. Its product lines include allografts—cryopreserved human tissue grafts used in vascular reconstruction—embolectomy catheters for removing blood clots from arteries, thrombectomy catheters for venous thrombi removal, and various synthetic and biologic grafts and patches. LeMaitre also provides human tissue cryopreservation services. The company distributes its products globally through direct sales to hospitals in over 25 countries and through distributors in more than 70 countries across North America, Europe, and Asia-Pacific. Founded in 1986 and headquartered in Burlington, Massachusetts, LeMaitre serves vascular surgeons performing both open surgical procedures and minimally invasive interventions, with the majority of its revenue generated from the United States market.